Download PDF
CC BY-NC-ND 4.0 · Indian J Radiol Imaging 2014; 24(02): 139-148
DOI: 10.4103/0971-3026.134399
Abdominal Radiology

Imaging and intervention in prostate cancer: Current perspectives and future trends

Sanjay Sharma
Department of Radiodiagnosis, All Institute of Medical Sciences, New Delhi, India
› Author Affiliations
› Further Information
  PDF Download Permissions and Reprints

Abstract

Prostate cancer is the commonest malignancy in men that causes significant morbidity and mortality worldwide. Screening by digital rectal examination (DRE) and serum prostate-specific antigen (PSA) is used despite its limitations. Gray-scale transrectal ultrasound (TRUS), used to guide multiple random prostatic biopsies, misses up to 20% cancers and frequently underestimates the grade of malignancy. Increasing the number of biopsy cores marginally increases the yield. Evolving techniques of real-time ultrasound elastography (RTE) and contrast-enhanced ultrasound (CEUS) are being investigated to better detect and improve the yield by allowing "targeted" biopsies. Last decade has witnessed rapid developments in magnetic resonance imaging (MRI) for improved management of prostate cancer. In addition to the anatomical information, it is capable of providing functional information through diffusion-weighted imaging (DWI), magnetic resonance spectroscopy (MRS), and dynamic contrast-enhanced (DCE) MRI. Multi-parametric MRI has the potential to exclude a significant cancer in majority of cases. Inclusion of MRI before prostatic biopsy can reduce the invasiveness of the procedure by limiting the number of cores needed to make a diagnosis and support watchful waiting in others. It is made possible by targeted biopsies as opposed to random. With the availability of minimally invasive therapeutic modalities like high-intensity focused ultrasound (HIFU) and interstitial laser therapy, detecting early cancer is even more relevant today. [18F]--fluorodeoxyglucose positron emission tomography/computed tomography ( 18 FDG PET/CT) has no role in the initial evaluation of prostate cancer. Choline PET has been recently found to be more useful. Fluoride-PET has a higher sensitivity and resolution than a conventional radionuclide bone scan in detecting skeletal metastases.

Keywords

Biopsy - contrast‑enhanced ultrasonography - elastography - magnetic resonance imaging - positron emission tomography


Publication History

Article published online:
02 August 2021

© 2014. Indian Radiological Association. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 Three Year Report of Population Based Cancer Registries (2009-2011). National Centre for Disease Informatics and Research. National Cancer Registry Programe, ICMR. Feb 2013. p. 57.
  • 2 Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.
  • 3 Okihara K, Shiraishi T, Ukimura O, Mizutani Y, Kawauchi A, Miki T. Current trends in diagnostic and therapeutic principles for prostate cancer in Japan. Int J Clin Oncol 2008;13:239-43.
  • 4 Syrigos KN, Karapanagiotou E, Harrington KJ. Prostate cancer in the elderly. Anticancer Res 2005;25:4527-33.
  • 5 Bostwick DG, Eble JN. Urological surgical pathology. St. Louis: Mosby; 2007. p. 468.
  • 6 Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL; ISUP grading committee. The 2005 International Society of Urologic Pathology (ISUP) Consensus Conference on Gleason grading of Prostatic Carcinoma. Am J Surg Pathol 2005;29:1228-42.
  • 7 Schröder FH, van der Maas P, Beemsterboer P, Kruger AB, Hoedemaeker R, Rietbergen J, et al. Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 1998;90:1817-23.
  • 8 Gretzer MB, Partin AW. PSA markers in prostate cancer detection. Urol Clin North Am 2003;30:677-86.
  • 9 Wilson SS, Crawford ED. Screening for prostate cancer: Current recommendations. Urol Clin North Am 2004;31:219-26.
  • 10 Carter HB, Partin AW. Diagnosis and staging of prostate cancer. In: Retik AB, Vaughan ED Jr, Wein AJ, editors. Campbell′s Urology. 8 th ed. Philadelphia, Pa: WB Saunders Co; 2002. p. 3055-79.
  • 11 Shteynshlyuger A, Andriole GL. Prostate cancer: To screen or not to screen?. Urol Clin North Am 2010;37:1-9.
  • 12 Derweesh IH, Rabets JC, Patel A, Jones JS, Zippe C. Prostate biopsy: Evolving indications and techniques. Contemp Urol 2004;16:28-32.
  • 13 Djavan B, Remzi M, Marberger M. When to biopsy and when to stop biopsying. Urol Clin North Am 2003;30:253-62.
  • 14 Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European Study. N Eng J Med 2009;360:1320-8.
  • 15 Chun FK, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PF, et al. Prostate Cancer Gene 3 (PCA3): Development and Internal validation of a novel biopsy nomogram. Eur Urol 2009;56:659-67.
  • 16 Norberg M, Egevad L, Holmberg L, Sparén P, Norlén BJ, Busch C. The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer. Urology 1997;50:562-6.
  • 17 Naughton CK, Smith DS, Humphrey PA, Catalona WJ, Keetch DW. Clinical and pathologic tumor characteristics of prostate cancer as a function of the number of biopsy cores: A retrospective study. Urology 1998;52:808-13.
  • 18 Patel AR, Jones JS, Rabets J, DeOreo G, Zippe CD. Para-sagittal biopsies add minimal information in repeat saturation prostatic biopsy. Urology 2004;63:87-9.
  • 19 Djavan B, Ravery V, Zlotta A, Dobronski P, Dobrovits M, Fakhari M, et al. Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: When should we stop? J Urol 2001;166:1679-83.
  • 20 Noguchi M, Stamey TA, McNeal JE, Yemoto CM. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: Lack of prediction of tumor significance for men with non palpable prostate cancer. J Urol 2001;166:104-9.
  • 21 Taneja SS. Imaging in the Diagnosis and Management of Prostate Cancer. Rev Urol 2004;6:101-13.
  • 22 Persti JC Jr, Chang JJ, Bhargava V, Shinohara K. The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: Results of a prospective clinical trial. J Urol. 2000;163:163-6.
  • 23 Babaian RJ, Toi A, Kamoi K, Troncoso P, Sweet J, Evans R, et al. A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy. J Urol 2000;163:152-7.
  • 24 Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part 1: Screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011;59:61-71.
  • 25 Srinivas V, Mehta H, Amin A, Choudhary R, Gadgil N, Ravishanker D, et al. Carcinoma of the prostate- stage at initial presentation. Int Urol Nephrol 1995;27:419-22.
  • 26 Gupta NP, Ansari MS, Das SC. Transrectal ultrasound guided biopsy for detecting early prostate cancer: An Indian experience. Indian J Cancer 2005;42:151-4.
  • 27 Ismail M, Peterson RO, Alexander AA, Newschaffer C, Gomella LG. Colour Doppler imaging in predicting the biologic behavior of prostate cancer: Correlation with disease-free survival. Urology 1997;50:906-12.
  • 28 Kirby RS. Pre-treatment staging of prostate cancer: Recent advances and future prospects. Prostate Cancer Prostatic Dis 1997;1:2-10.
  • 29 Taverna G, Morandi G, Seveso M, Giusti G, Benetti A, Colombo P, et al. Colour Doppler and microbubble contrast agent ultrasonography do not improve cancer detection rate in Transrectal systemic prostate biopsy sampling. BJU Int 2011;108:1723-7.
  • 30 Halpern EJ, Frauscher F, Strup SE, Nazarian LN, O′Kane P, Gomella LG. Prostate: High-frequency Doppler US Imaging for cancer detection. Radiology 2002;225:71-7.
  • 31 Halpern EJ, Ramey JR, Strup SE, Frauscher F, McCue P, Gomella LG. Detection of prostate cancer with contrast enhanced sonography using intermittent harmonic imaging. Cancer 2005;104:2373-83.
  • 32 Mitterberger M, Aigner F, Pinggera GM, Steiner E, Rehder P, Ulmer H, et al. Contrast-enhanced colour doppler-targeted prostate biopsy: Correlation of a subjective blood-flow rating scale with the histopathological outcome of the biopsy. BJU Int 2010;106:1315-8.
  • 33 Brock M, von Bodman C, Sommerer F, Loppenberg B, Klien T, Deix T, et al. Comparison of real-time elastography with gray-scale Ultrasonography for detection of organ-confined prostate cancer and extra capsular extension: A prospective analysis using whole mount sections after radical prostatectomy. BJU Int 2011;108:E217-22.
  • 34 Bloch BN, Rofsky NM, Baroni RH, Marquis RP, Pedrosa I, Lenkinski RE. 3 Tesla magnetic resonance imaging of the prostate with combined pelvic phased-array and endorectal coils; Initial experience (1). Acad Radiol 2004;11:863-7.
  • 35 Narayanan R, Werahera PN, Barqawi A, Crawford ED, Shinohara K, Simoneau AR, et al. Adaptation of a 3D prostate cancer atlas for transrectal ultrasound guided target-specific biopsy. Phys Med Biol 2008;53:N397-406.
  • 36 Stamey TA, Donaldson AN, Yemoto CE, McNeal JE, Sözen S, Gill H. Histological and clinical findings in 896 consecutive prostates treated only with radical retropubic prostatectomy: Epidemiologic significance of annual changes. J Urol 1998;160:2412-7.
  • 37 Augustin H, Hammerer PG, Blonski J, Graefen M, Palisaar J, Daghofer F, et al. Zonal location of prostate cancer: Significance for disease-free survival after radical prostatectomy?. Urology 2003;62:79-85.
  • 38 Puech P, Betrouni N, Makni N, Dewalle AS, Villers A, Lemaitre L. Computer-assisted diagnosis of prostate cancer using DCE-MRI data: Design, implementation and preliminary results. Int J Comput Assist Radiol Surg 2009;4:1-10.
  • 39 Katahira K, Takahara T, Kwee TC, Oda S, Suzuki Y, Morishita S, et al. Ultra-high-b-value diffusion-weighted MR imaging for the detection of prostate cancer: Evaluation in 201 cases with histopathological correlation. Eur Radiol 2011;21:188-96.
  • 40 Tamada T, Sone T, Jo Y, Toshimitsu S, Yamashita T, Yamamoto A, et al. Apparent diffusion coefficient values in peripheral and transition zones of the prostate: Comparison between normal and malignant prostatic tissues and correlation with histologic grade. J Magn Reson Imaging 2008;28:720-6.
  • 41 Tanimoto A, Nakashima J, Kohno H, Shinmoto H, Kuribayashi S. Prostate cancer screening: The clinical value of diffusion-weighted imaging and dynamic MR imaging in combination with T2-weighted imaging. J Magn Reson Imaging 2007;25:146-52.
  • 42 Ren J, Huan Y, Wang H, Zhao H, Ge Y, Chang Y, et al. Diffusion-weighted imaging in normal prostate and differential diagnosis of prostate diseases. Abdom Imaging 2008;33:724-8.
  • 43 Mazaheri Y, Shukla-Dave A, Hricak H, Fine SW, Zhang J, Inurrigarro G, et al. Prostate cancer: Identification with combined diffusion-weighted MR imaging and 3D 1H MR spectroscopic imaging-correlation with pathologic findings. Radiology 2008;246:480-8.
  • 44 Reinsberg SA, Payne GS, Riches SF, Ashley S, Brewster JM, Morgan VA, et al. Combined use of diffusion-weighted MRI and 1H MR spectroscopy to increase accuracy in prostate cancer detection. AJR Am J Roentgenol 2007;188:91-8.
  • 45 Kingsley PB, Monahan WG. Selection of optimum b factor for diffusion weighted magnetic resonance imaging assessment of ischemic stroke. Magn Reson Med 2004;51:996-1001.
  • 46 Pickles MD, Gibbs P, Sreenivas M, Turnbull LW. Diffusion-weighted imaging of normal and malignant prostatic tissue at 3.0T. J Magn Reson Imaging 2006;23:130- 4.
  • 47 Hambrock T, Somford DM, Huisman HJ, van Oort IM, Witjes JA, Hulsbergen-van de Kaa CA, et al. Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer. Radiology 2011;259:453-61.
  • 48 Kim JH, Kim JK, Park BW, Kim N, Cho KS. Apparent diffusion coefficient: Prostate cancer versus noncancerous tissue according to anatomical region. J Magn Reson Imaging 2008;28:1173-9.
  • 49 Blackledge MD, Leach MO, Collins DJ, Koh DM. Computed diffusion weighted MR imaging may improve tumor detection. Radiology 2011;261:573-81.
  • 50 Rosenkrantz AB, Mannelli L, Kong X, Niver BE, Berkman DS, Babb JS, et al. Prostate cancer: Utility of fusion of T2-weighted and high b-value diffusion-weighted images for peripheral zone tumor detection and localization. J Magn Reson Imaging 2011;34:95-100.
  • 51 Hoeks CM, Barentsz JO, Hambrock T, Yakar D, Somford DM, Heijmink SW, et al. Prostate cancer: MULTIPARAMETRIC MR imaging for detection, localization, and staging. Radiology 2011;261:46-66.
  • 52 Kurhanewicz J, Vigneron DB, Hricak H, Narayan P, Carroll P, Nelson SJ. Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution. Radiology 1996;198:795-805.
  • 53 Choi YJ, Kim JK, Kim N, Kim KW, Choi EK, Cho KS. Functional MR Imaging of prostate cancer. Radiographics 2007;27:63-75.
  • 54 Zakian KL, Sircar K, Hricak H, Chen HN, Shukla- Dave A, Eberhardt S, et al. Correlation of proton MR spectroscopic imaging with Gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology 2005;234:804-14.
  • 55 Yu KK, Scheidler J, Hricak H, Vigneron DB, Zaloudek CJ, Males RG, et al. Prostate cancer: Prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiology 1999;213:481-8.
  • 56 Verma S, Turkbey B, Muradyan N, Rajesh A, Cornud F, Haider MA, et al. Overview of dynamic contrast-enhanced MRI in prostate cancer diagnosis and management. AJR Am J Roentgenol 2012;198:1277-88.
  • 57 Tofts PS. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging 1997;7:91-101.
  • 58 Sung YS, Kwon HJ, Park BW, Cho G, Lee CK, Cho KS, et al. Prostate cancer detection on dynamic contrast-enhanced MRI: Computer-aided diagnosis versus single perfusion parameter maps. AJR Am J Roentgenol 2011;197:1122-9.
  • 59 Fütterer JJ, Heijmink SW, Scheenen TW, Veltman J, Huisman HJ, Vos P, et al. Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology 2006;241:449-58.
  • 60 De Visschere P, Oosterlinck W, De Meerleer G, Villeirs G. Clinical and Imaging tools in the early diagnosis of prostate cancer, A review. JBR-BTR 2010;93:62-70.
  • 61 Kumar V, Jagannathan NR, Kumar R, Thulkar S, Gupta SD, Hemal AK, et al. Transrectal ultrasound-guided biopsy of prostate voxels identified as suspicious of malignancy on three-dimensional (1) H MR spectroscopic imaging in patients with abnormal digital rectal examination or raised prostate specific antigen level of 4-10 ng/ml. NMR Biomed 2007;20:11-20.
  • 62 Kaplan I, Oldenberg NE, Meskell P, Blake M, Church P, Holupka EJ. Real time MRI-ultrasound image guided stereotactic prostate biopsy. Magn Reson Imaging 2002;20:295-9.
  • 63 Hirahara N, Ukimora O, Fujihara A. Video: Hybrid real time ultrasound system fused with virtual 3D CT/MRI for image guided surgery. J Urol 2010;183 suppl:185.
  • 64 Lattouf JB, Grubb RL 3 rd , Lee SJ, Bjurlin MA, Albert P, Singh AK, et al. Magnetic resonance imaging-directed transrectal ultrasonography-guided biopsies in patients at risk of prostate cancer. BJU Int 2007;99:1041-6.
  • 65 Atalar E, Menard C. MR-Guided interventions for prostate cancer. Magn Reson Imaging Clin N Am 2005;13:491-504.
  • 66 White S, Hricak H, Forstner R, Kurhanewicz J, Vigneron DB, Zaloudek CJ, et al. Prostate cancer: Effect of post biopsy hemorrhage on interpretation of MR images. Radiology 1995;195:385-90.
  • 67 Lawrentschuk N, Haider MA, Daljeet N, Evans A, Toi A, Finelli A, et al. ′Prostatic evasive anterior tumours′: The role of magnetic resonance imaging. BJU Int 2010;105:1231-6.
  • 68 McNeal JE, Redwine EA, Frieha FS, Stamey TA. Zonal distribution of prostatic adenocarcinoma: Correlation with histologic pattern and direction of spread. Am J Surg Pathol 1988;12:897-906.
  • 69 Mozer P, Baumann M, Daanen V, Bordenave M, Thibault F, Conort P, et al. Free hand 3D-TRUS prostate biopsies mapping. J Urol 2010;183 Suppl:833.
  • 70 Fütterer JJ, Engelbrecht MR, Jager GJ, Hartman RP, King BF, Hulsbergen-Van de Kaa CA, et al. Prostate cancer: Comparison of local staging accuracy of pelvic phased-array coil alone versus integrated endorectal-pelvic phased-array coils. Local staging accuracy of prostate cancer using endorectal coil MR imaging. Eur Radiol 2007;17:1055-65.
  • 71 Girouin N, Mège-Lechevallier F, Tonina Senes A, Bissery A, Rabilloud M, Maréchal JM, et al. Prostate dynamic contrast-enhanced MRI with simple visual diagnostic criteria: Is it reasonable? Eur Radiol 2007;17:1498-509.
  • 72 Villeirs GM, L Verstraete K, De Neve WJ, De Meerleer GO. Magnetic resonance imaging anatomy of the prostate and periprostatic area: A guide for radiotherapists. Radiother Oncol 2005;76:99-106.
  • 73 Dickinson L, Ahmed HU, Allen C, Barentsz JO, Carey B, Futterer JJ, et al. Magnetic Resonance Imaging for the Detection, localization, and characterization of prostate cancer: Recommendations from a European consensus meeting. Eur Urol 2011;59:477-94.